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Background: The objective of the present study was to elucidate the humoral and cellular immune response
mechanisms by which a reformulated inactivated chimeric PCV1-2 vaccine reduces the PCV2 viremia. Forty PCV2
seronegative 3-week-old pigs were randomly divided into the following four groups: vaccinated challenged (T01),
vaccinated non-challenged (T02), non-vaccinated challenged (T03), and non-vaccinated non-challenged (T04)
animals. The pigs in groups T01 and T02 were immunized with a reformulated inactivated chimeric PCV1-2 vaccine
(Fostera™ PCV; Pfizer Animal Health) administered as a 2.0 ml dose at 21 days of age. At 35 days of age (0 days
post-challenge), the pigs in groups T01 and T03 were inoculated intranasally with 2 ml each of PCV2b.
Results: A reduction of PCV2 viremia coincided with the appearance of both PCV2-specific neutralizing antibodies
(NA) and interferon-γ-secreting cells (IFN-γ-SCs) in the vaccinated animals. However, the presence of anti-PCV2 IgG
antibodies did not correlate with the reduction of PCV2 viremia. Lymphocyte subset analysis indicated that the
numbers of CD3+ and CD4+ cells increased in vaccinated animals but the numbers of CD4+ cells decreased
transiently in non-vaccinated animals. The observation of a delayed type hypersensitivity response in only the
vaccinated animals also supports a CD4+ cell-associated protective cellular immune response induced by the
reformulated inactivated chimeric PCV1-2 vaccine.
Conclusions: The induction of PCV2-specific NA and IFN-γ-SCs, and CD4+ cells by the reformulated inactivated
chimeric PCV1-2 vaccine is the important protective immune response leading to reduction of the PCV2 viremia
and control of the PCV2 infection. To our knowledge this is the first demonstration of protective humoral and
cellular immunity induced by the reformulated inactivated chimeric PCV1-2 vaccine and its effect on reduction of
PCV2 viremia by vaccination.
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Porcine circovirus type 2 (PCV2) is one of the most
economically important swine pathogens worldwide.
The first commercial PCV2 vaccine was used under
special license in France and Germany in 2004, 13
years after postweaning multisystemic wasting syn-
drome (PMWS) was first identified and reported in
western Canada [1]. In addition to PMWS, PCV2 is
also associated with a number of diseases and syn-
dromes, collectively referred to as porcine circovirus-
associated disease (PCVAD) [2,3].
Currently, 5 commercial PCV2 vaccines are available
worldwide and differ in their antigen [1]. One vaccine
(Circovac, Merial) is based on the classical approach of
an inactivated oil-adjuvanted vaccine. Three subunit vac-
cines (Circoflex, Boehringer Ingelheim; Circumvent
PCV, Intervet/Merck; Porcillis PCV, Schering-Plough/
Merck) are based on an open reading frame 2 (ORF2;
capsid) protein expressed in the baculovirus system.
Another vaccine (Suvaxyn PCV2 One Dose, Pfizer
Animal Health/Fort Dodge Animal Health) is based on a
chimeric PCV1-2 virus containing the genomic back-
bone of the non-pathogenic PCV1, with the ORF2
capsid gene replaced by that of PCV2 [4]. In 2008, Pfizer
Animal Health temporarily removed the inactivated
chimeric PCV1-2 vaccine product from the markets be-
cause a chimeric PCV1-2 virus was incidentally detected
in the field due to incomplete inactivation of the vaccine
[5]. In August 2011, a reformulated version of the
chimeric PCV1-2 vaccine under a new brand name
(Fostera™ PCV, Pfizer Animal Health) re-entered the
market.
PCV2 viremia plays a central role in the develop-
ment of PMWS. High levels of PCV2 viremia are
associated with the development of PCVAD [6,7].
Reductions in the PCV2 viremia have coincided with
the appearance of both PCV2-specific neutralizing
antibodies (NA) and interferon γ-secreting cells (IFN-
γ-SCs) in PCV2-infected animals [6-9]. Therefore, the
induction of PCV2-specific NA and IFN-γ-SCs by
commercial PCV2 vaccines is a critical parameter to
evaluate the efficacy of PCV2 vaccines in the control
of PCV2 infection. It has been reported that subunit
and inactivated PCV2 vaccines elicit PCV2-specific
NA and IFN-γ-SCs [10,11]. Although the former
inactivated chimeric PCV1-2 vaccine induced PCV2-
specific NA [12], little is known regarding the protect-
ive immunity by which the reformulated inactivated
chimeric PCV1-2 vaccine reduces the PCV2 viremia.
The objective of present study is to elucidate the
mechanisms how humoral and cellular immune re-
sponse induced by the reformulated inactivated chimeric
PCV1-2 vaccine reduces PCV2 viremia under experi-
mental conditions.Methods
Animals and housing
A total of 40 colostrum-fed, cross-bred, conventional pig-
lets were purchased at 14 days of age from a commercial
farm. All piglets were negative for porcine reproductive
and respiratory syndrome virus (PRRSV) and Mycoplasma
hyopneumoniae according to routine serological testing.
All piglets were negative for PCV1-2a and PCV2 viremia
by real-time polymerase chain reaction (PCR), respectively
[13,14]. All piglets were also seronegative against PCV2
according to commercial ELISA (Synbiotics, Lyon,
France). All pigs were housed in an environmentally con-
trolled building as previously described [15].
Experimental design
A total of 40 piglets were randomly divided into 4
groups (10 pigs per group). The pigs in groups T01 and
T02 were immunized with an inactivated chimeric
PCV1-2 vaccine (Fostera™ PCV; Pfizer Animal Health
Inc.) administered as a 2.0 ml dose at 21 days of age
based on the manufacturer’s recommendations. At 35
days of age [0 days post-challenge (dpc)], the pigs in groups
T01 and T03 were inoculated intranasally with 2 ml each
of a PCV2b [strain SNUVR000463; 5th passage; 1.0 × 105
tissue culture infective dose of 50% (TCID50)/ml]. The
pigs in group T04 remained unvaccinated and unchal-
lenged, and served as the negative control group. The pigs
in each group were housed separately within the facility.
Blood samples and nasal swabs were collected at −14, 0,
14, and 28 dpc. All pigs were euthanized for necropsy at
28 dpc and superficial inguinal lymph nodes were
collected for histopathology and immunohistochemistry.
All of the methods were previously approved by the Seoul
National University Institutional Animal Care and Use
Committee.
Quantification of PCV2 DNA in blood and nasal swab
DNA was extracted from serum and nasal samples using
the QIAamp DNA mini kit. DNA extracts were used to
quantify PCV2 genomic DNA copy numbers by real-
time PCR as previously described by Gagnon et al.
(2008) [14]. DNA extracts from serum samples were also
used to detect PCV1-2a DNA by real-time PCR as previ-
ously described by Shen et al. (2010) [13].
Serology
The serum samples were tested using the commercial
PCV2 ELISA IgG (Synbiotics, Lyon, France) and serum
virus neutralization (SVN) test [16].
Preparation of PCV2 antigen
The same PCV2 strain used for challenge in the present
study, was propagated in PCV-free PK15 cells to a titer of
104 TCID50/ml and treated with two freeze-thaw cycles.
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virus present in cell culture by ultracentrifugation at
100,000x g at 4°C for 3 h. The virus pellet was resus-
pended with PBS. The concentrated PCV2 was inactivated
by exposing to an 8 W germicidal UV lamp at a distance
of 15 cm for 1 h. Immunoperoxidase assay was performed
to confirm the inactivation of virus as previously described
by Rodriguez-Arrioja et al. (2000) [17].
Delayed type hypersensitivity
The delayed type hypersensitivity (DTH) test was
performed on 40 piglets from 4 groups at 5 weeks of age
(2 weeks after vaccination; 0 dpc). Piglets were injected
intradermally on the left inguinal area with 250 μg of
PCV2 antigen from infected PK15 cells. Phytohemaglu-
tin (PHA; Roche Diagnostics GmbH; 20 μg/ml in 0.1 ml)
and saline (0.1 ml) were used as positive and negative
controls, respectively. The mean diameters of the in-
duration at the test site were measured with a
micrometer 36 h after injection.
Direct immunofluorescence assay
Cryosections (about 7 μm in thickness) were prepared
from skin biopsy specimens in DTH test. Sections were
transferred to microscope slides treated with poly-L-ly-
sine. The slides were fixed with acetone for 20 min and
then air-dried. The slides were then covered with 50 μl
of mouse anti-pig CD4a conjugated with R-phycoerythrin
(R-PE) (1:100 dilution; SouthernBiotech, Birmingham, AL,
USA) and incubated for 60 min at 37°C in a moisture
chamber. After three washing steps with PBS, the slides
were mounted in buffered glycerin for observation by
fluorescence microscopy.
Enzyme-linked immunospot (ELISPOT) assay
The numbers of PCV2-specific interferon-γ-secreting
cells (IFN-γ-SCs) were determined in peripheral blood
mononuclear cells (PBMCs) at −14, 0, 14, and 28 dpc as
previously described [18]. Briefly, 100 μl containing
2×106 PBMCs in RPMI 1640 medium supplemented
with 10% fetal bovine serum (HyClone Laboratories,
Inc., SelectScience, Bath, UK) were seeded into plates
pre-coated with anti-porcine IFN-γ monoclonal antibody
(5 μg/ml, MABTECH, Mariemont, OH, USA) and incu-
bated with 100 μl of PCV2 antigen (20 μg/ml), phyto-
hemagglutinin (10 μg/ml, Roche Diagnostics GmbH,
Mannheim, Germany) as a positive control, or PBS as a
negative control for 40 h at 37°C in a 5% humidified
CO2 atmosphere. Then, the wells were washed five times
with PBS (200 μl per well). Thereafter, procedure was
followed by manufacturer’s instructions using a commer-
cial ELISPOT assay kit (MABTECH, Mariemont, OH,
USA). Spots on the membranes were read by an auto-
mated ELISpot reader (AID ELISpot Reader, AIDGmbH, Strassberg, Germany). The results were
expressed as the number of responding cells per million
PBMCs.
Flow cytometry
PBMCs were incubated with R-PE- or FITC-conjugated
mouse monoclonal antibodies (antiswine CD3 [R-PE]
and CD4 [R-PE and FITC]; SouthernBiotech, Birming-
ham, AL, USA) for 30 min at 4°C in the dark and
washed twice with PBS containing 0.1% sodium azide
and 0.1% bovine serum albumin. Cells stained with con-
jugated antibodies were resuspended immediately in
supplemented RPMI 1640 medium. Cells were analyzed
using a FACSCalibur flow cytometer (Becton Dickinson)
as previously described by Sosa et al. (2009) [19].
Histopathology and immunohistochemistry
For the morphometric analysis of histopathological le-
sion score and PCV2 antigen score in superficial in-
guinal lymph nodes were collected at necropsy. In each
sample, three sections were randomly selected and
examined “blindly” as previously described by Kim et al.
(2011) [15]. The scores of lesions in lymph nodes ranged
from 0 (No lymphoid depletion or granulomatous re-
placement) to 5 (severe lymphoid depletion and granu-
lomatous replacement), and the PCV2 antigen scores
were obtained by counting the number of PCV2 positive
cells per unit area (0.25 mm2).
Statistical analysis
Continuous data (DTH response, PCV2 DNA, PCV2
serology, PCV2-specific IFN-γ-SCs, and lymphocyte sub-
sets) were analyzed with a one-way analysis of variance
(ANOVA). If a one-way ANOVA was significant (P < 0.05),
pairwise testing using Tukey’s adjustment was performed.
Discrete data (lymphoid lesion score and PCV2 antigen
score, and proportion of viremic pigs) were analyzed by
Chi-square and Fisher’s exact test.
The Pearson’s correlation coefficient was used to as-
sess the relationship among viremia, serum virus
neutralization titer, PCV2-specific IFN-γ-SCs, and the
Spearman’s rank correlation coefficient was used to as-
sess lymphoid lesion score and PCV2 antigen score. A
value of p < 0.05 was considered significant.
Results
PCV2 DNA in sera and nasal swabs
PCV2 DNA was not detected in serum and nasal sam-
ples from any of pigs at 0 dpc. Vaccinated challenged
(T01) animals had a significantly lower number of gen-
omic copies of PCV2 in the blood than non-vaccinated
challenged (T03) animals at 14 and 28 days post challenge
(dpc; p < 0.001, Figure 1). The percentage of viremic pigs
was significantly lower in vaccinated challenged animals
Figure 1 Mean values of the genomic copy number of porcine circovirus type 2 DNA in serum and nasal swabs from vaccinated
challenged (T01; □ for serum and ■ for nasal swab) and non-vaccinated challenged (T03; ◯ for serum and ● for nasal swab) animals.
Variation is expressed as the standard deviation. Significant difference is indicated at p value <0.001*.
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vaccinated challenged animals (10/10 at 14 and 28 dpc,
p < 0.05). Vaccinated challenged animals had a sig-
nificantly lower number of genomic copies of PCV2
in the nasal swab than non-vaccinated challenged ani-
mals at 14 and 28 dpc (p < 0.001, Figure 1). The per-
centage of nasal shedders was significantly lower in
vaccinated challenged animals (4/10 at 14 and 28
dpc) than in non-vaccinated challenged animals (10/10 at
14 and 28 dpc, p < 0.05). The number of genomic copies
of PCV2 in the blood correlated with that of PCV2 in the
nasal swabs (T01: r2 = 0.921, p = 0.042 and T03: r2 = 0.972,
p = 0.002). No PCV2 DNA was detected in the blood and
nasal swabs from vaccinated non-challenged (T02) and
non-vaccinated non-challenged (T04) animals throughout
the experiment. No PCV1-2a DNA was detected in the
blood from vaccinated (T01 and T02) and non-vaccinated
(T03 and T04) animals by real-time PCR at −14, 0, 14,
and 28 dpc.Anti-PCV2 IgG antibodies
At the time of PCV2 vaccination (3 weeks of age; -14 dpc),
pigs in all 4 groups were seronegative against PCV2. Anti-
PCV2 IgG antibody titers were significantly higher in vac-
cinated challenged (T01) and vaccinated non-challenged
(T02) animals than in non-vaccinated challenged (T03)
animals at 0, 14, and 28 dpc. Anti-PCV2 IgG antibody
titers were not detected in non-vaccinated non-challenged
(T04) animals throughout the experiment. Anti-PCV2
IgG antibody titers did not correlate with the number ofgenomic copies of PCV2 in the blood (T01: r2 = −0.332,
p = 0.075 and T03: r2 = −0.105, p = 0.126).Neutralizing antibodies
At the time of PCV2 vaccination (3 weeks of age, -14 dpc),
no significant differences in NA titers were detected among
the 4 groups. The NA titers were significantly higher in
vaccinated challenged (T01) and vaccinated non-
challenged (T02) animals than in non-vaccinated chal-
lenged (T03) animals group at 0, 14, and 28 dpc. The NA
titers were not detected in non-vaccinated non-challenged
(T04) animals throughout the experiment (Figure 2). The
NA titers correlated inversely with the number of genomic
copies of PCV2 in the blood (T01: r2 = −0.712, p = 0.012
and T03: r2 = −0.635, p = 0.031).PCV2-specific interferon- γ-secreting cells
PCV2-specific IFN-γ-SCs were not observed in the iso-
lated PBMCs of pigs from the 4 groups at −14 dpc.
PCV2-specific IFN-γ-SCs increased sharply in vaccinated
challenged (T01) and vaccinated non-challenged (T02)
animals at 0 dpc (2 weeks after vaccination). At 0 and 14
dpc, the mean numbers of PCV2-specific IFN-γ-SCs
were significantly higher in vaccinated challenged (T01)
and vaccinated non-challenged (T02) animals compared
to non-vaccinated challenged (T03) animals (p < 0.05).
At 28 dpc, the mean numbers of PCV2-specific IFN-γ-
SCs were significantly higher in vaccinated challenged
(T01) than in vaccinated non-challenged (T02) and non-
vaccinated challenged (T03) animals (p < 0.01). PCV2-
Figure 2 Mean values of the serum neutralizing antibodies (NA) titer in the different groups; vaccinated challenged (T01; □),
vaccinated non-challenged (T02; ▲), non-vaccinated challenged (T03; ○), and non-vaccinated non-challenged (T04; ♦) animals.
Variation is expressed as the standard deviation. Significant difference (T01 and T02 vs. T03 and T04) is indicated at p value <0.01*. Significant
difference (T01 vs. T02) is indicated at p value <0.05†.
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from non-vaccinated non-challenged (T04) animals
throughout the experiment (Figure 3).
PCV2-specific IFN-γ-SCs also correlated inversely with
the number of genomic copies of PCV2 in the blood (T01:
r2 = −0.685, p = 0.022 and T03: r2 = −0.625, p = 0.028).Figure 3 Mean number of porcine circovirus type 2-specific interferon
vaccinated non-challenged (T02; ▲), non-vaccinated challenged (T03
Variation is expressed as the standard deviation. Significant difference (T01
difference (T01 vs. T02) is indicated at p value <0.01†.Delayed type hypersensitivity
At 36 h after intradermal injection of the PCV2 antigen,
vaccinated animals showed DTH responses consisted of
induration and erythematous nodules (Figure 4a). Histo-
pathologically, perivascular infiltrations of lymphocytes
were observed in the dermis (Figure 4b). The specific-γ-secreting cells (IFN-γ-SCs) in vaccinated challenged (T01; □),
; ○), and non-vaccinated non-challenged (T04; ♦) animals.
and T02 vs. T03 and T04) is indicated at p value <0.05*. Significant
Figure 4 Delayed type hypersensitivity induced by inactivated
chimeric PCV1-2 vaccine in vaccinated challenged (T01)
animals. (a) erythematous lesion were grossly observed in the skin.
(b) Perivascular infiltration of lymphocytes (black arrows) was seen in the
dermis. (c) CD4+ cells (white arrows) were seen in the perivascular zone.
Table 1 Mean number of delayed type hypersensitivity
(DTH) response size, microscopic lymphoid lesion score
and immunohistochemical Porcine circovirus type 2
(PCV2) antigen score in lymph node from vaccinated
challenged (T01), vaccinated non-challenged (T02), non-
vaccinated challenged (T03), and non-vaccinated non-
challenged (T04) animals
Groups
T01 T02 T03 T04
DTH 15.38* ± 1.87 14.20* ± 4.26 2.19 ± 0.08 1.98 ± 1.09
Lymphoid
lesion score
0.40† ± 0.54 - 1.67 ± 0.57 -
PCV2 antigen
score
6.18† ± 4.79 - 44.12 ± 9.07 -
*Significant difference (T01 and T02 vs. T03 and T04) is indicated at
p value < 0.01. †Significant difference (T01 vs. T03) is indicated at p value < 0.05.
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lar zone (Figure 4c). The positive signals were mainly
seen in the cytoplasm of cells.
The skin reaction regressed slowly at 48 h after in-
jection and completely disappeared. DTH responseswere not observed in the controls. The vaccinated
animals in groups T01 and T02 and non-vaccinated ani-
mals in groups T03 and T04 showed DTH responses to
the nonspecific mitogen PHA. The PHA DTH response
size was not significantly different between vaccinated
(T01 and T02) and non-vaccinated (T03 and T04) ani-
mals. The vaccinated (T01 and T02) animals displayed
significantly greater PCV2-specific DTH responses than
the non-vaccinated (T03 and T04) animals (p < 0.01,
Table 1). DTH responses to saline injection were not
observed in any pigs. DTH response correlated with
PCV2-specific IFN-γ-SCs (T01: r2 = 0.637, p = 0.015 and
T03: r2 = 0.219, p = 0.218).Identification of lymphocyte subsets
Vaccinated challenged (T01) and vaccinated non-
challenged (T02) animals showed an increase in the rela-
tive proportions of CD3+ and CD4+ cells at 0 dpc
compared with non-vaccinated challenged (T03) and
non-vaccinated non-challenged (T04) animals (p < 0.05).
Vaccinated challenged (T01) animals showed an increase
in the relative proportions of CD3+ and CD4+ cells at 14
dpc, and in the relative proportions of CD4+ cells at 28
dpc compared with non-vaccinated challenged (T03) and
non-vaccinated non-challenged (T04) animals (p < 0.05).
At 14 dpc, the relative proportions of CD3+ cells were
significantly higher in vaccinated non-challenged (T02)
animals than non-vaccinated challenged (T03) and non-
vaccinated non-challenged (T04) animals (p < 0.05,
Figure 5). The number of CD4+ cells correlated with
the number of PCV2-specific IFN-γ-SCs in the blood
(T01: r2 = 0.624, p = 0.025, T02: r2 = 0.589, p = 0.047,
and T03: r2 = 0.527, p = 0.041). The number of CD4+ cells
also correlated with the DTH response (T01: r2 = 0.597,
p = 0.023 and T03: r2 = 0.176, p = 0.365).
Figure 5 Lymphocyte subsets analysis in the different groups; CD3+ (■) and CD4+(□) from vaccinated challenged (T01) animals, CD3+
(▲) and CD4+(△) from vaccinated non-challenged (T02) animals, CD3+ (●) and CD4+(◯) from non-vaccinated challenged (T03) animals,
and CD3+ (♦) and CD4+(◇) from non-vaccinated non-challenged (T04) animals. Variation is expressed as the standard deviation. Significant
difference (T01 and T02 vs. T03 and T04) is indicated at p value <0.05*. Significant difference (T02 vs. T03) is indicated at p value <0.05†.
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The histopathological lymphoid lesion scores were sig-
nificantly lower in the vaccinated challenged (T01) ani-
mals than in the non-vaccinated challenged (T03)
animals (p < 0.05, Table 1). The histopathological lymph-
oid lesion scores correlated with the number of genomic
copies of PCV2 in the blood (T01: r2 = 0.870, p = 0.041
and T03: r2 = 0.892, p = 0.023). The mean number of
PCV2-positive cells per unit area of lymph node was sig-
nificantly lower in vaccinated challenged (T01) animals
than in non-vaccinated challenged (T03) animals (p < 0.01,
Table 1). The PCV2 antigen scores correlated with the
number of genomic copies of PCV2 in the blood
(T01: r2 = 0.855, p = 0.038 and T03: r2 = 0.872, p = 0.047).
Discussion
Quantitation of the PCV2 viremia could predict PCV2
infection status. Several studies have already shown that
PCV2 DNA levels in serum are higher in pig with
PMWS than in healthy, subclinically infected pigs [20-22].
Hence, the reduction of PCV2 viremia by the PCV2 vaccine
plays a critical role in controlling PCV2 infection. In
the present study, the reformulated inactivated chimeric
PCV1-2 vaccine is able to induce PCV2-specific NA
and IFN-γ-SCs in vaccinated animals. This protective
immunity induced by the reformulated inactivated
chimeric PCV1-2 vaccine correlated with the reduction
of PCV2 viremia in pigs challenged experimentally with
solely PCV2 as induced by other commercial PCV2vaccines did [10,23]. However, the presence of anti-
PCV2 IgG antibodies did not correlate with the reduc-
tion of PCV2 viremia. The reformulated inactivated
chimeric PCV1-2 vaccine also reduced the PCV2 load
in nasal shedding in vaccinated animals, thereby de-
creasing the risk of transmission to other pigs via a
nasal route and decreasing the amount of PCV2 circu-
lating among the pigs.
IFN-γ, which is produced by PCV2-specific IFN-γ-SCs,
is a key immunoregulatory cytokine that controls the
differentiation of naïve CD4+ into CD4+ cells and med-
iates cellular immunity against viral infections [24]. Our
results are further supported by the observation that ele-
vated numbers of CD4+ cells are seen in vaccinated ani-
mals only. Lymphocyte subset analysis indicated that the
numbers of CD3+ and CD4+ cells increased in vacci-
nated animals but the numbers of CD4+ cells decreased
transiently in non-vaccinated animals. The selective loss
of CD3+ and CD4+ cells that is observed in pigs with
PMWS [25,26] may impair the immune system in the
pigs and result in co-infections with other viral and bac-
terial pathogens; co-infections are frequently observed in
pigs with PMWS under field conditions [27,28]. Because
CD4+ cells promote a DTH response [29], the DTH
response observed in only vaccinated animals also sup-
ports a CD4+ cell-associated protective cellular immune
response that is induced by the reformulated inactivated
chimeric PCV1-2 vaccine. PCV2-specific memory T
lymphocytes induced by this chimeric PCV1-2 vaccine
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tion of the PCV2 antigen. Hence, the induction of
PCV2-specific NA and IFN-γ-SCs by the reformulated
inactivated chimeric PCV1-2 vaccine is the important
protective immune response that leads to reduce the
PCV2 viremia and control the PCV2 infection.
Well-controlled experimental studies are necessary to
elucidate the protective humoral and cellular immune
response induced by the reformulated inactivated
chimeric PCV1-2 vaccine to reduce PCV2 viremia be-
cause the results can be affected by factors such as en-
vironment, feed, pig source, immune status and
inoculums. Under field conditions, PCV2 continues to
circulate among pigs within the herd and the possibility
of exposure and re-exposure to the virus by horizontal
transmission occurs once one animal becomes infected.
To our knowledge this is the first demonstration of pro-
tective humoral and cellular immunity induced by the
reformulated inactivated chimeric PCV1-2 vaccine and
its effect on reduction of PCV2 viremia by vaccination.
Conclusions
The reformulated inactivated chimeric PCV1-2 vaccine
is able to induce PCV2-specific NA and IFN-γ-SCs in
vaccinated animals. This protective immunity induced
by the reformulated inactivated chimeric PCV1-2 vac-
cine correlated with the reduction of PCV2 viremia in
pigs challenged experimentally with solely PCV2.
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